spacer
home > pmps > autumn 2008 > integrating isolation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Integrating Isolation

Remaining competitive in pharmaceutical development and production can be a challenge as it becomes more complex to get products through clinical trials and then to eventually produce them. In order to remain competitive, pharmaceutical companies need to develop products faster and more cost-effectively. At the same, time, they need to protect workers from increasingly hazardous drugs in both the clinical trials phase and during the manufacturing process.

In order to meet these trends costeffectively, many pharmaceutical companies will need to increase automation and flexibility within their facilities, while separating the production environment from operators. Combining these initiatives within a single technology platform is making it economically feasible to meet these challenges and still compete effectively.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Felix Nink studied Mechanical Engineering at Koblenz University. He has worked for Robert Bosch GmbH Packaging Technology since 2000, beginning his career as a Mechanical Designer in the capsule filling and checkweighing department. He gained experience as Application Engineer and Project Leader of several turnkey encapsulation projects for the pharmaceutical industry. Since 2004, Felix has been a Product Manager, with responsibility for capsule filling and checkweighing machines worldwide.
spacer
Felix Nink
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health finds growing eConsent adoption forecasts and the importance of eClinical integration in latest “State of eConsent” survey

PHILADELPHIA, PA – January 16, 2020: Signant Health, released the findings from its latest “State of eConsent” report today, highlighting the sentiments, successes, and challenges of eConsent practitioners around the world. Join Signant Health’s webinar on February 12, 2020 at 11am ET or 3pm ET to learn more about the findings.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Pharmapack Europe 2020

5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement